KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Accumulated Expenses (2017 - 2025)

Moderna (MRNA) has disclosed Accumulated Expenses for 9 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 2.87% to $1.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Dec 2025, down 2.87% year-over-year, with the annual reading at $1.4 billion for FY2025, 2.87% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $1.4 billion at Moderna, up from $1.2 billion in the prior quarter.
  • The five-year high for Accumulated Expenses was $2.2 billion in Q3 2023, with the low at $753.0 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $1.4 billion, with a median of $1.4 billion recorded in 2024.
  • The sharpest move saw Accumulated Expenses soared 1268.59% in 2021, then crashed 38.13% in 2024.
  • Over 5 years, Accumulated Expenses stood at $1.5 billion in 2021, then skyrocketed by 42.73% to $2.1 billion in 2022, then decreased by 14.42% to $1.8 billion in 2023, then decreased by 20.63% to $1.4 billion in 2024, then fell by 2.87% to $1.4 billion in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $1.4 billion, $1.2 billion, and $987.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.